IGMS News and Press, IGM Biosciences Inc. From 02/12/24

2024-02-12 15:09:25 ET Summary IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024. The global lupus market is projected to grow t...

2024-02-10 08:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-09 17:10:51 ET More on IGM Biosciences IGM Biosciences: A New Approach To Antibodies, But Not A Value Right Now IGM Biosciences to cut 22% of workforce, shut down blood cancer programs IGM Biosciences GAAP EPS of -$1.04 beats by $0.21, revenue of $0.51M misse...

2024-02-09 10:00:22 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenh...

2024-01-30 16:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-05 05:50:19 ET Summary IGM Biosciences is developing antibodies that are different from most monoclonal antibodies currently in use. They have two main pipeline projects focused on cancer and rheumatologic disease. The company is facing financial challenges but has ext...

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan H...

2023-12-14 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...